CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact editor@advancedpractitioner.com

Kathryn Ciccolini, AGACNP-BC, DNP, MSN, OCN
CAR-T/BMT Clinical Program Manager
Bone Marrow and Stem Cell Transplantation Program
Mount Sinai Hospital

CAR T-Cell Therapy Resource Center

Interview With Linda Ramsdell, MSN, FNP-BC, OCN: Administering CAR T-Cell Therapy in the Outpatient Setting

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

BMT infonet: CAR T-Cell therapy

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

NCCN: Immunotherapy Side Effects - CAR T-Cell Therapy

Journal of Cancer Policy

Health-Related Quality of Life Data Collected in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Clinical Trials

Blood

Response to SARS-CoV-2 Vaccination in Patients After Hematopoietic Cell Transplantation and CAR T-Cell Therapy

Nature Reviews Clinical Oncology

Preparing for CAR T Cell Therapy: Patient Selection, Bridging Therapies and Lymphodepletion

Expert Opinion on Investigational Drugs

CAR-T Cell Therapy for Triple-Negative Breast Cancer and Other Solid Tumors: Preclinical and Clinical Progress

Nature Medicine

Gut Microbiome Correlates of Response and Toxicity Following Anti-CD19 CAR T Cell Therapy

Transplantation and Cellular Therapy

Change in Neurocognitive Performance Among Patients With Non-Hodgkin’s Lymphoma in the First Year After CAR T-Cell Therapy

Blood Cancer Discovery

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

Biology of Blood and Marrow Transplantation

American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States

JAMA Oncology

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

Frontiers in Oncology

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

Fast Facts #12: BCMA Targets